Rubbish Talk app Cut the spin.
Read the facts. Suspicious of a headline?
Check it.
Rubbish Check
CNBC Top News · 24 October 2026 source

“Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer”

R3/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates CNBC's headline that Amgen's Imdelltra-Imfinzi combo "cuts risk of death by 58%" a 3/10 because the figure is a real, correctly-attributed relative-risk reduction from Amgen's own trial, but the headline omits the absolute survival numbers (21.1 vs 12.7 months) and the fact this maintenance-therapy use isn't yet an approved indication.
The Verdict
Lightly altered. The 58% figure is accurate and correctly framed as a company claim ("Amgen says"), not stated as independent fact, which is the right call for unpublished trial data presented at a conference. The one-iteration slip is using the relative-risk number alone in the headline without its absolute companion, a common pharma-reporting shortcut that flatters the drug more than the raw survival-month gap would on its own.

What actually happened

Amgen's Imdelltra, added to AstraZeneca's Imfinzi as maintenance therapy, produced a 58% reduction in the relative risk of death versus Imfinzi alone in a late-stage trial of extensive-stage small cell lung cancer patients. Full results from a late-stage trial released Saturday show that adding Amgen's immunotherapy Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer, a fast-growing disease that has spread beyond the lung where it began. The drug combination extended their median overall survival to 21.1 months compared with 12.7 months with AstraZeneca's drug alone, the trial found. The data was presented at a medical conference, not yet reflected in an approved label change.

Key facts

  • Relative risk reduction: 58% lower risk of death with the combo versus Imfinzi alone, per the trial Amgen released.
  • Absolute survival (the context the headline skips): median overall survival to 21.1 months compared with 12.7 months with AstraZeneca's drug alone… half of patients in the group that took the combination regimen were alive for at least roughly 21 months.
  • One-year survival: Amgen said nearly 80% of patients who started taking both drugs were alive at one year compared with 53% receiving Imfinzi alone.
  • Trial design caveat: The trial tested the combo as a maintenance therapy in patients who received initial treatment with Imfinzi and chemotherapy, and whose cancer had not progressed.
  • Approval status not yet matching the headline's framing: Imdelltra is currently approved for patients whose small cell lung cancer has progressed while they are on, or after, platinum-based chemotherapy. The maintenance/earlier-line use in this trial is investigational.
  • What the trial didn't test: The study, which was presented at a major cancer meeting called the European Society for Medical Oncology Congress, did not test whether the combination was better than other first-line treatment approaches.
  • Disease scale: There are roughly 31,000 new small cell lung cancer cases in the U.S. each year, and an estimated 60% to 70% of those people are diagnosed with extensive-stage disease.

What to watch for

Watch whether the 21.1-month median survival figure holds or improves with longer follow-up; the lead investigator flagged it could "evolve further," based on a smaller Phase 1 cohort where benefit held for years. Also watch for FDA review of this maintenance-setting use, since the headline implies clinical availability that doesn't exist yet, and for any coverage omitting the no-head-to-head-comparison caveat against other first-line regimens.

About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
Share this CheckXFacebookLinkedInEmail